Omeros (OMER) has been on a downward spiral lately with significant selling pressure. After declining 54.8% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is ov ...

Group 1 - The article discusses the author's first treatment of Omeros in 2025, following extensive coverage in the previous year [1] - The author emphasizes the learning process involved in investing, viewing failures as tuition and successes as lessons learned, particularly in the healthcare sector [2] - The author has a beneficial long position in Omeros shares, indicating a personal investment interest [3] Group 2 - The author may engage in buying or selling shares of any mentioned company within the next 72 hours, suggesting potential volatility or changes in position [4] - Seeking Alpha clarifies that past performance does not guarantee future results and that no specific investment advice is being provided [5]

Omeros Corporation (NASDAQ:OMER) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Jennifer Williams - Investor and Media relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman & CEO David Borges - Chief Accounting Officer Nadia Dac - Chief Commercial Officer Conference Call Participants Steve Brozak - WBB Securities Operator Good afternoon, and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode. A ...

Omeros Corp (OMER) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Jennifer Cook Williams - PrincipalGregory Demopulos - Founder, Chairman, CEO & PresidentDavid Borges - VP of Finance, Chief Accounting Officer & TreasurerSteve Brozak - President & Managing PartnerNadia Dac - CCO Operator Good afternoon, and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen only mode. After the company's remarks, we will conduct a question and answer s ...

Omeros Corp (OMER) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Jennifer Cook Williams - PrincipalGregory Demopulos - Founder, Chairman, CEO & PresidentDavid Borges - VP of Finance, Chief Accounting Officer & TreasurerSteve Brozak - President & Managing PartnerNadia Dac - CCO Operator Good afternoon, and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen only mode. After the company's remarks, we will conduct a question and answer s ...

Omeros Corp (OMER) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen only mode. After the company's remarks, we will conduct a question and answer session. Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website for one week from today. I'll turn the call over to Jennifer Williams, Investor Relations for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34475 OMEROS CORPORATION (Exact name of registrant as specified in its charter) Washington 91-1663741 (State ...

Exhibit 4.2 OMEROS CORPORATION and COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION as Trustee SECOND SUPPLEMENTAL INDENTURE Dated as of May 14, 2025 C R O S S R E F E R E N C E TA B L E * | Tru | s | t | I | n | d | e | n | tu | r | e | | | | | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | A | c | t | I | n | d | e | n | tu | r | e ...

Omeros Corporation OMER on Thursday established the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia (AML).AML is the most fatal form of leukemia. It accounts for approximately 80% of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow.Omeros’ OncotoX program for AML consists of proprietary targeted, engineered molecules (about half the size of an antibody) that deliver a toxic payload within the can ...

Financial Data and Key Metrics Changes - The net loss for Q4 2024 was $31.4 million, or $0.54 per share, compared to a net loss of $32.2 million, or $0.56 per share in Q3 2024 [6][58] - For the full year 2024, the net loss was $156.8 million, or $2.70 per share [6][58] - As of December 31, 2024, the company had over $90 million in cash and investments on hand [7][59] Business Line Data and Key Metrics Changes - Research and development expenses in Q4 were heavily focused on narsoplimab and Zaltenibart [59] - OMIDRIA royalties for Q4 totaled $10.1 million based on net sales of $33.6 million, an increase from $9.3 million in Q3 [63] Market Data and Key Metrics Changes - The market size for paroxysmal nocturnal hemoglobinuria (PNH) is reported to be $3.9 billion in 2023 and projected to exceed $10 billion by 2032 [36] Company Strategy and Development Direction - The company plans to independently launch narsoplimab in the U.S. while seeking partnerships for ex-U.S. commercialization [124][126] - The focus is on restructuring the balance sheet and exploring various funding options, including partnerships and royalty monetization [8][104] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the data supporting the BLA resubmission for narsoplimab, highlighting significant survival benefits [77][78] - The company is preparing for the market launch of narsoplimab, with a strong foundation of awareness among transplant physicians [116] Other Important Information - The company is advancing Zaltenibart for C3 glomerulopathy and has received a rare pediatric disease designation from the FDA for this indication [46][47] - OMS527, aimed at treating addictions, has received funding from the National Institute on Drug Abuse for a Phase 1b clinical trial [52] Q&A Session Summary Question: Can you tell us why you believe the BLA submission is strong? - Management highlighted that the statistical analysis plan was created with FDA's agreement, and the results showed a more than three-fold improvement in survival for narsoplimab-treated patients [76][78] Question: Can you comment on pricing for narsoplimab? - Management indicated that pricing plans have not been disclosed but are expected to be in line with other complement inhibitors used in TA-TMA [91][92] Question: What is the strategy for funding and managing the balance sheet? - Management stated that they are aware of the need for balance sheet management and are exploring various options, including restructuring convertible notes and seeking additional capital [104][105] Question: Where does the company stand on manufacturing scalability for narsoplimab? - Management confirmed that they have sufficient drug supply to support the launch and initial market demand for narsoplimab [112] Question: How does the company view its long-term strategy regarding partnerships? - Management plans to launch narsoplimab independently in the U.S. while seeking partnerships for ex-U.S. commercialization, with a focus on leveraging their deep pipeline [124][126]